Advances in cardiovascular safety of SGLT-2 inhibitors and GLP-1 receptor agonists / 药学实践杂志
Journal of Pharmaceutical Practice
; (6): 496-500, 2020.
Artigo
em Chinês
| WPRIM (Pacífico Ocidental)
| ID: wpr-829951
Biblioteca responsável:
WPRO
ABSTRACT
Type 2 diabetes is a high risk factor for atherosclerotic cardiovascular disease. Studies have found that SGLT-2 inhibitor and GLP-1 receptor agonists have cardiovascular protective effects in patients with type 2 diabetes and cardiovascular disease. Therefore, from the aspects of cardiovascular safety test and its Meta-analysis and net-like Meta-analysis, the research progress of cardiovascular safety of SGLT-2 inhibitors and GLP-1 receptor agonists is summarized.
Texto completo:
Disponível
Base de dados:
WPRIM (Pacífico Ocidental)
Tipo de estudo:
Fatores de risco
Idioma:
Chinês
Revista:
Journal of Pharmaceutical Practice
Ano de publicação:
2020
Tipo de documento:
Artigo